Agenda
3:00 PM - 3:30 PM    Registration and Networking
3:30 PM - 5:00 PM    Industry Panel
5:00 PM - 6:30 PM    Networking Reception

From alliance to funding, Big Pharma and established biotech companies are increasingly investing in emerging companies. This Panel brings together executives from these larger companies to identify the type of deals now available to smaller companies, how to secure them, and how to manage them.

Questions that will be raised include:
� What are the best approaches for identifying a good partner?
� What type of partnerships are commonly used? And is your company a best candidate for a simple license, or a full blown joint venture, or a M&A;?
� What about the rising of Big Pharma VC Funds?
� What are the strategies for attracting, securing and structuring strategic investments?
� How the Larger Bio-Companies� needs differ from VCs� needs?
� What are the key contract terms to be negotiated?
� What are the strategic reasoning behind different kinds partnerships?
� Effects on existing and potential future collaboration partners and other strategic decisions.
� Pros and cons of a small company partnering with a larger company.
� �Dos� and �don�ts� of managing these important relationships.

Our Panel discussions are candid, interactive and informal. We want you to walk away with the real story behind how things work so you can make it happen yourself. This Panel will be followed by a Networking Reception.

Speakers | Partial List
� Dr. Yael Weiss, Director of Licensing & External Research, Merck Research Laboratories, Merck & Co., Inc.
� Dr. David Donabedian, Vice President of Strategic Alliances, US ceedd, GlaxoSmithKline


Cost & Registration
� Regular Price: $60
� Partners' Network: $50
� BioCenter Members: Free (please RSVP to Aur�lie)
� On-site Registration: add $10 to the above
This event is typically sold out, so early pre-registration is recommended to avoid disappointment on the day!

Register to the full 2010 Industry Panel Series and save!
Full Panel Series registration includes access to:
� How to Become a VC Magnet? | Mar. 25
� Financing Alternatives | Jun. 3
� Doing Deals with Big Pharma | Sep. 23
� 6th Annual Trends in Financing Investor Panel & Holiday Celebration | Dec. 9

Venue
Orrick, Herrington & Sutcliffe LLP
1000 Marsh Road
Building 1100
Menlo Park, CA 94025-1015
Click here for Venue Directions»


Speakers Bios

Dr. Yael Weiss, Director of Licensing & External Research, Merck Research Laboratories, Merck & Co., Inc.
Yael completed her MSc and PhD in molecular genetics at the Weizmann Institute of Science, Rehovot, Israel and obtained her medical degree at Hadassah Medical Center, affiliated with The Hebrew University of Jerusalem, Israel. After practicing medicine for a few years, Yael joined an Israeli venture capital firm as a vice president responsible for analyzing and maintaining deal flow, and then moved on to become a medical and business development director at Genzyme Israel. Yael joined MSD Israel as medical director in the beginning of 2004 and in 2007 she joined Merck's Licensing group in San Francisco as a scientific scout responsible for identification of licensing opportunities emanating from the West Coast.

Dr. David Donabedian, Vice President of Strategic Alliances, GSK's Centre of Excellence for External Drug Discovery (ceedd)
Dr. Donabedian is the Vice President of Strategic Alliances in GSK's Centre of Excellence for External Drug Discovery (ceedd). In his role, Dr. Donabedian is primarily responsible for identifying and evaluating new business opportunities for the U.S. ceedd. Prior to joining the ceedd, Dr. Donabedian served as a principal of his own consultancy practice providing business development services to emerging biotechnology companies. He has sourced and closed several agreements with biopharmaceutical companies and academic institutions.
Dr. Donabedian also serves as the Treasurer of the Healthy Lifespan Institute, a non-profit organization dedicated to extending healthy lifespan through studying, educating, and testing the rapid advances in the science and medicine of aging.
Dr. Donabedian�s previous senior level positions include CEO, COO and VP of Business Development for Tutorzilla, BioChemics, and Surface Logix. Dr. Donabedian also worked as a Sr. Manager in Accenture�s Strategic Services Consulting Group serving both in the U.S. and internationally, with assignments focusing on R&D; post-merger integration, business unit strategy, and resource planning. Prior to Accenture, Dr. Donabedian held senior level positions at Sentry� Products, a Union Carbide life science venture (now Dow Chemical), where he headed a product development team specializing in developing and patenting a broad range of technologies to the life sciences industries. Dr. Donabedian began his research career as a scientist with SciMed Life Systems, a division of Boston Scientific, where he developed novel bioadhesives to treat abdominal aortic aneurysms. Dr. Donabedian is an inventor/co-inventor on several patents and has published several papers in peer-reviewed journals in the field of polymer science.
Since 2006, Dr. Donabedian has served as a member of University of Massachusetts Lowell Plastics Advisory Committee. He is also as an Alumni Network Advisor for the University of North Carolina Business School. Dr. Donabedian served as a Mentor for the Durham Scholars program and was invited as a guest lecturer at the University of Indiana�s Kelly School of Business and University of North Carolina�s Business School. He received an A.B. from St. Anselm College, a Ph.D. in Polymer Chemistry from the University of Massachusetts Lowell and an M.B.A. from the University of North Carolina Chapel Hill where he was a Deloitte Case Cup Challenge Winner.